Related Experiment Videos
[Histopathology and tumor markers]
Hiroshi Kijima1, Yoshito Ueyama, Yoshiyuki Osamura
1Department of Pathology, Tokai University School of Medicine, Isehara 259-1193.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|January 28, 2004
Summary
Immunohistochemical tumor markers like CEA, CA19-9, and p53 aid in cancer diagnosis and prognosis. These markers, detected via immunohistochemistry, help identify cancer types and predict patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Context:
- Serum tumor markers are crucial for cancer detection and diagnosis.
- Advances in immunohistochemistry enable sensitive detection of various tumor markers.
- This article reviews key immunohistochemical markers used in cancer diagnostics.
Purpose:
- To highlight the utility of immunohistochemical analyses for detecting diverse tumor markers.
- To discuss specific markers such as Carcinoembryonic antigen (CEA), CA19-9, and p53.
- To explore the role of these markers in cancer diagnosis and prognosis.
Summary:
- Immunohistochemistry detects serum tumor markers, cellular components, antigens, and oncogene products.
- Carcinoembryonic antigen (CEA) and CA19-9 are associated with colorectal, gastrointestinal, and pancreatic cancers, potentially promoting metastasis.
- p53 overexpression, detected immunohistochemically, is a marker for adenocarcinoma and indicates altered cell growth regulation.
Impact:
- Immunohistochemical markers provide valuable histopathological diagnostic information.
- These markers serve as prognostic predictors, aiding in patient outcome assessment.
- Understanding marker roles in metastasis can inform therapeutic strategies.